Aimmune confirms $2B Nestle acquisition

August 31, 2020

Less than a minute

On Monday, Aimmune Therapeutics announced that it had agreed to Nestle’s $2 billion dollar acquisition. Yahoo Finance’s Anjalee Khemlani sat down with Jayson Dallas, Aimmune’s CEO, to speak about the acquisition and about the peanut allergy treatment development.

View Article Origin Here

August 31, 2020

Less than a minute